Diogenes of Sinope Wednesday, 11/14/18 08:39:57 AM Re: None Post # of 646 Canntab Corporate Update Reaching a milestone in its development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC, OTCQX: EMMBF). Dissolution testing indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing pivotal batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab’s unique solid oral dose delivery systems. https://ih.advfn.com/p.php?pid=nmona&article=78686577 GLTA!